These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 12725899)
1. Antidyskinetic effects of risperidone on animal models of tardive dyskinesia in mice. Carvalho RC; Silva RH; Abílio VC; Barbosa PN; Frussa-Filho R Brain Res Bull; 2003 Apr; 60(1-2):115-24. PubMed ID: 12725899 [TBL] [Abstract][Full Text] [Related]
2. Differential striatal levels of TNF-alpha, NFkappaB p65 subunit and dopamine with chronic typical and atypical neuroleptic treatment: role in orofacial dyskinesia. Bishnoi M; Chopra K; Kulkarni SK Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1473-8. PubMed ID: 18554768 [TBL] [Abstract][Full Text] [Related]
3. Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine. Tada M; Shirakawa K; Matsuoka N; Mutoh S Psychopharmacology (Berl); 2004 Oct; 176(1):94-100. PubMed ID: 15083255 [TBL] [Abstract][Full Text] [Related]
4. Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. Chouinard G J Clin Psychopharmacol; 1995 Feb; 15(1 Suppl 1):36S-44S. PubMed ID: 7537286 [TBL] [Abstract][Full Text] [Related]
5. Comparative neurochemical changes associated with chronic administration of typical and atypical neuroleptics: implications in tardive dyskinesia. Bishnoi M; Kumar A; Chopra K; Kulkarni SK Indian J Exp Biol; 2007 Feb; 45(2):175-9. PubMed ID: 17375557 [TBL] [Abstract][Full Text] [Related]
6. Multidose risperidone treatment evaluated in a rodent model of tardive dyskinesia. Gao XM; Cooper T; Suckow RF; Tamminga CA Neuropsychopharmacology; 2006 Sep; 31(9):1864-8. PubMed ID: 16319911 [TBL] [Abstract][Full Text] [Related]
7. Possible antioxidant and neuroprotective mechanisms of FK506 in attenuating haloperidol-induced orofacial dyskinesia. Singh A; Naidu PS; Kulkarni SK Eur J Pharmacol; 2003 Sep; 477(2):87-94. PubMed ID: 14519411 [TBL] [Abstract][Full Text] [Related]
13. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. Chouinard G; Jones B; Remington G; Bloom D; Addington D; MacEwan GW; Labelle A; Beauclair L; Arnott W J Clin Psychopharmacol; 1993 Feb; 13(1):25-40. PubMed ID: 7683702 [TBL] [Abstract][Full Text] [Related]
14. Improvement of debilitating tardive dyskinesia with risperidone. Rangwani SR; Gupta S; Burke WJ; Potter J Ann Clin Psychiatry; 1996 Mar; 8(1):27-9. PubMed ID: 8743646 [TBL] [Abstract][Full Text] [Related]
15. Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study. Bai YM; Yu SC; Lin CC J Clin Psychiatry; 2003 Nov; 64(11):1342-8. PubMed ID: 14658949 [TBL] [Abstract][Full Text] [Related]
16. Cannabidiol prevents haloperidol-induced vacuos chewing movements and inflammatory changes in mice via PPARγ receptors. Sonego AB; Prado DS; Vale GT; Sepulveda-Diaz JE; Cunha TM; Tirapelli CR; Del Bel EA; Raisman-Vozari R; Guimarães FS Brain Behav Immun; 2018 Nov; 74():241-251. PubMed ID: 30217539 [TBL] [Abstract][Full Text] [Related]